Trials / Completed
CompletedNCT03782805
Effect of Vitamin D Supplementation on Inflammatory Markers
Effect of Vitamin D Treatment on Some Inflammatory Markers in Non-obese Lebanese Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Université d'Auvergne · Academic / Other
- Sex
- All
- Age
- 60 Years – 72 Years
- Healthy volunteers
- Not accepted
Summary
Previous studies have shown that improving vitamin D status among the elderly may lead to an improvement in some inflammatory markers, especially with patients with type 2 diabetes. The aim of our trial is study the effect of vitamin D supplementation on inflammatory markers in patients having type 2 diabetes.
Detailed description
Vitamin D was shown crucial for insulin secretion and glucose homeostasis. Furthermore, one of the markers of type 2 diabetes is low-grade inflammation, which can be the result of an elevated circulation of cytokines. High amounts of circulating inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) contribute significantly to insulin resistance in muscle and adipose tissues. The aim of this randomized, controlled, double blind study is to examine the effect of vitamin D supplementation on some inflammatory markers in older Lebanese patients having type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | cholecalciferol (Euro-Pharm International, Canada) | The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months |
| DIETARY_SUPPLEMENT | Placebo tablet | The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months |
Timeline
- Start date
- 2018-05-09
- Primary completion
- 2018-06-07
- Completion
- 2018-07-09
- First posted
- 2018-12-20
- Last updated
- 2018-12-21
Locations
1 site across 1 country: Lebanon
Source: ClinicalTrials.gov record NCT03782805. Inclusion in this directory is not an endorsement.